KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesBeginning Cash BalanceCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Change in Acquisitions & Divestments: 2018-2023

Historic Change in Acquisitions & Divestments for Esperion Therapeutics (ESPR) over the last 4 years, with Jun 2023 value amounting to $17.5 million.

  • Esperion Therapeutics' Change in Acquisitions & Divestments rose 250.00% to $17.5 million in Q2 2023 from the same period last year, while for Jun 2023 it was $105.5 million, marking a year-over-year increase of 138.99%. This contributed to the annual value of $42.5 million for FY2023, which is 37.50% down from last year.
  • As of Q2 2023, Esperion Therapeutics' Change in Acquisitions & Divestments stood at $17.5 million, which was down 30.00% from $25.0 million recorded in Q1 2023.
  • In the past 5 years, Esperion Therapeutics' Change in Acquisitions & Divestments ranged from a high of $45.9 million in Q1 2019 and a low of $2.2 million during Q3 2020.
  • Moreover, its 2-year median value for Change in Acquisitions & Divestments was $25.0 million (2023), whereas its average is $22.1 million.
  • In the last 5 years, Esperion Therapeutics' Change in Acquisitions & Divestments plummeted by 89.62% in 2020 and then spiked by 250.00% in 2023.
  • Quarterly analysis of 4 years shows Esperion Therapeutics' Change in Acquisitions & Divestments stood at $5.0 million in 2019, then tumbled by 89.62% to $2.2 million in 2020, then reached $30.0 million in 2022, then surged by 250.00% to $17.5 million in 2023.
  • Its Change in Acquisitions & Divestments was $17.5 million in Q2 2023, compared to $25.0 million in Q1 2023 and $30.0 million in Q4 2022.